5. References

  1. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed March 1, 2022.
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed March 1, 2022.
  3. Dabigatran etixilate mesylate capsules (Pradaxa®) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., June 2021.
  4. Dabigatran etixilate mesylate pellets (Pradaxa®) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., June 2021.
  5. Apixaban tablets (Eliquis®) package insert. Bristol-Myers Squibb Company, September 2021.
  6. Edoxaban tablets (Savaysa®) package insert. Daiichi Sankyo, Inc., September 2021.
  7. Rivaroxaban tablets and granules for suspension (Xarelto®) package insert. Janssen Pharmaceuticals, Inc., January 2022.
  8. Smith, I. Response to PREA non-compliance letter. Portola Pharmaceuticals. October 2020. Accessed March 1, 2022.
  9. U.S. Food and Drug Administration. FDA approved first oral blood thinning medication for children. June 2021. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children#:~:text=Today%2C%20the%20U.S.%20Food%20and,by%20injection%20for%20at%20least. Accessed March 1, 2022. 
  10. U.S. Food and Drug Administration. FDA approved drug to treat, help prevent types of blood clots in certain pediatric populations. December 2021. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-help-prevent-types-blood-clots-certain-pediatric-populations#:~:text=FDA%20has%20approved%20Xarelto%20(rivaroxaban,days%20of%20injectable%20or%20intravenous. Accessed March 1, 2022.
  11. Stevens SM, Woller SC, Kreuziger LB, et al. Executive summary: antithrombotic therapy for vte disease: second update of the chest guideline and expert panel report. CHEST. 2021;160(6):2247-2259.
  12. Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (Diversity): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. The Lancet Haematology. 2021;8(1):e22-e33.
  13. Brandão LR, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491-504.
  14. Bosch A, Albisetti M. Management of venous thromboembolism in children: current recommendations and therapeutic options. Ther Clin Risk Manag. 2020;16:673-679.
  15. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology. 2020;7(1):e18-e27.
  16. McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for children post‐fontan procedure: insights from the universe study. Journal of the American Heart Association. 2021;10(22):e021765.